Clinical Trial: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
Study Status: Completed
Recruit Status: RECRUITING
Condition: Metastatic Castration-resistant Prostate Cancer
Study Type: INTERVENTIONAL
Official Title: Phase 2 Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor Targeting Agents (ARTA)
Brief Summary:
The goal of this clinical trial is to examine the safety and efficacy of ONC-392 in combination with lutetium Lu 177 vipivotide tetraxetan in metastatic castration resistant prostate cancer patient who have disease progressed on androgen receptor pathway inhibition.The main questions it aims to answer are (1) whether it is safe to combine ONC-392 with lutetium Lu 177 vipivotide tetraxetan, (2) whether the combination increases the radiographic progression free survival (rPFS).Participants will be randomized to two…
Read more